Cero Therapeutics Holdings, Inc. financial data

Symbol
CERO, CEROW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
201 Haskins Way, Suite 230, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
PHOENIX BIOTECH ACQUISITION CORP. (to 2/14/2024)
Latest financial report
10-Q/A - Q3 2024 - Nov 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 46.3 %
Debt-to-equity -73.1 % +54.6%
Return On Equity 68.8 % +38.9%
Return On Assets -128 % -314%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 150M shares
Common Stock, Shares, Outstanding 9.07M shares
Entity Public Float 2.69M USD -98.5%
Common Stock, Value, Issued 907 USD +931%
Weighted Average Number of Shares Outstanding, Basic 49.7M shares +448%
Weighted Average Number of Shares Outstanding, Diluted 49.7M shares +448%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.16M USD +38.9%
General and Administrative Expense 7.95M USD +128%
Operating Income (Loss) -14.1M USD -187%
Nonoperating Income (Expense) 5.13M USD -6.42%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -308K USD -313%
Income Tax Expense (Benefit) 25.8K USD -57.4%
Net Income (Loss) Attributable to Parent -8.98M USD -46.1%
Earnings Per Share, Basic -0.42 USD/shares +40%
Earnings Per Share, Diluted -0.42 USD/shares +40%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 96.9K USD -79.6%
Assets, Current 3.71M USD
Property, Plant and Equipment, Net 625K USD
Operating Lease, Right-of-Use Asset 1.65M USD
Assets 6.49M USD -23.4%
Accounts Payable, Current 6.67M USD
Employee-related Liabilities, Current 49.1K USD
Accrued Liabilities, Current 1.69M USD
Liabilities, Current 9.42M USD +96.3%
Operating Lease, Liability, Noncurrent 772K USD
Liabilities 10.2M USD -26.9%
Retained Earnings (Accumulated Deficit) -71.6M USD -420%
Stockholders' Equity Attributable to Parent -3.7M USD +73.1%
Liabilities and Equity 6.49M USD -23.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -198K USD +35.8%
Net Cash Provided by (Used in) Investing Activities -100K USD
Common Stock, Shares Authorized 45.4M shares
Common Stock, Shares, Issued 9.07M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -298K USD +3.35%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.38M USD +2740%
Deferred Tax Assets, Valuation Allowance 608K USD +1.81%
Cash and Cash Equivalents, Period Increase (Decrease) -308K USD
Deferred Tax Assets, Gross 608K USD +1.81%
Operating Lease, Liability 1.7M USD
Depreciation 114K USD -1.33%
Lessee, Operating Lease, Liability, to be Paid 1.88M USD
Operating Lease, Liability, Current 931K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 726K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 990K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 182K USD
Preferred Stock, Shares Issued 4M shares
Deferred Federal Income Tax Expense (Benefit) 182K USD
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 1.03M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 400K USD
Interest Expense 14.4K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%